Skip to content Skip to footer
Subscribe Now
NEWS

Nxera Pharma Partners with Synmosa to Commercialize Quviviq Across Eight Asia-Pacific Markets

Shots: Nxera Pharma, through its subsidiary Nxera Pharma Japan, entered an exclusive license, supply and commercialization agreement with Synmosa Biopharma for Quviviq (daridorexant), a treatment for insomnia, across Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand Synmosa will lead regulatory approvals, market access, marketing, distribution and sales across the eight markets, while…
2 hours ago

Read more

NEWS

Galderma to Acquire ZO Skin Health for $1.5B

Shots: Galderma signed an agreement to acquire 100% of ZO Skin Health for an enterprise value of $1.5B in an all-cash transaction, expanding its dermatological skincare portfolio alongside Cetaphil and Alastin ZO Skin Health offers more than 40 skincare products and serves over 16,500 physician, medical spa, and online accounts across more than 40 countries.…
3 hours ago

Read more

NEWS

Prelude Therapeutics and Lilly Collaborate to Evaluate PRT13722 Combinations in HR+/HER2- Breast Cancer

Shots: Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722, an oral selective KAT6A degrader, in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo) in pts. with HR+/HER2- breast cancer The combination cohorts are part of Prelude’s P-I study, supported by preclinical data demonstrating synergy between PRT13722, CDK4/6 inhibitors,…
4 hours ago

Read more

NEWS

Generate Biomedicines and Zealand Pharma Enter ~$1.2B AI-Driven Metabolic Disease Collaboration

Shots: Generate Biomedicines and Zealand Pharma entered a strategic collaboration to develop multispecific protein therapeutics for obesity and other metabolic diseases using Generate’s generative AI platform and Zealand Pharma’s metabolic health expertise Under the agreement, Generate will receive $30M upfront, up to $35M in early preclinical milestones, and is eligible for nearly $1.2B including potential development,…
7 hours ago

Read more

NEWS

BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer

Shots: BioNTech reported that its P-II/III AHEAD-MERIT study did not meet the first dual 1EP of progression-free survival (PFS) for BNT113 plus pembrolizumab vs pembrolizumab alone in 1L treatment of unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 The Independent Data Monitoring Committee recommended continuing the study to evaluate…
8 hours ago

Read more

NEWS

Kairos Pharma Reports Positive Interim P-II Data for ENV-105 in Metastatic Prostate Cancer

Shots: Kairos Pharma announced positive interim efficacy data from its ongoing P-II study evaluating ENV-105 (carotuximab) in combination with apalutamide in pts. with metastatic castration-resistant prostate cancer (mCRPC) The combination demonstrated a statistically significant improvement in progression-free survival, with median PFS of 17.7 mons. vs 2 mons. with apalutamide alone (P=0.0008) Following the interim results,…
October 6, 2026

Read more

Telix Pharmaceuticals
NEWS

Telix Reports First US Patients Dosed with FDA-Approved Pixclara for Glioma Imaging

Shots: Telix Pharmaceuticals reported that the first pts. in the US have been dosed with Pixclara (floretyrosine F-18), marking the start of commercial availability of the FDA-approved PET imaging drug for glioma Pixclara (IV) is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients one…
October 6, 2026

Read more

NEWS

Shionogi to Acquire IntraBio for $2B to Expand Rare Disease Portfolio

Shots: Shionogi announced a planned acquisition of IntraBio for $2.0B, adding AQNEURSA (levacetylleucine) and IntraBio’s rare disease capabilities to its portfolio; the transaction is expected to close between November and December 2026, subject to customary conditions and regulatory approvals AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease Type C…
October 6, 2026

Read more

NEWS

GE HealthCare to Acquire SOFIE Biosciences for $945M to Expand US PET Radiopharmaceutical Supply

Shots: GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945M in cash, with the transaction expected to close in 1H’27, subject to regulatory approvals and other closing conditions. If completed, SOFIE will become part of GE HealthCare’s PDx segment The acquisition will establish GE HealthCare’s footprint in the…
October 6, 2026

Read more

Load more